Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
TipRanksApr 26 16:23 ET
Express News | Bluebird bio Announces Receipt of Expected Notice From Nasdaq
ReutersApr 26 16:05 ET
Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio
Yahoo FinanceApr 17 05:50 ET
Express News | Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Moomoo 24/7Apr 16 16:26 ET
Express News | bluebird bio Shares Down 9% at $0.90 After the Bell Following Announcement of Delay in 10-Q Filing
Moomoo 24/7Apr 16 16:23 ET
Express News | bluebird bio Inc - Anticipates It Will Be Delayed in Filing Its Quarterly Report on Form 10-Q for the First Quarter of 2024
Moomoo 24/7Apr 16 16:08 ET
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Seeking AlphaApr 15 16:46 ET
Express News | Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across
Moomoo 24/7Apr 15 16:17 ET
Is Bluebird Bio Stock a Buy?
The Motley FoolApr 15 08:15 ET
Better Buy: Bluebird Bio Vs. Novavax
The Motley FoolApr 13 16:22 ET
Is This Beaten-Down Stock a Good Acquisition Target?
Yahoo FinanceApr 11 08:30 ET
Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireApr 11 08:00 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
TipRanksApr 8 22:00 ET
Bluebird Bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript
Yahoo FinanceApr 2 11:33 ET
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
The Motley FoolMar 29 05:20 ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
TipRanksMar 29 04:20 ET
Peeling Back The Layers: Exploring Bluebird Bio Through Analyst Insights
During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent rating
BenzingaMar 27 12:01 ET
RBC Capital Reiterates Sector Perform on Bluebird Bio, Maintains $6 Price Target
RBC Capital analyst Luca Issi reiterates bluebird bio with a Sector Perform and maintains $6 price target.
Analyst UpgradesMar 27 11:36 ET
Bluebird Biotech Set to Outperform Pessimistic Expectations – Broker | NASDAQ:BLUE
Proactive InvestorsMar 27 10:50 ET
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Dow JonesMar 27 08:44 ET
No Data
No Data